BRIEF published on 01/27/2025 at 22:20, 1 year ago Theralase's Interim Clinical Data to be Highlighted at 2025 AUA Annual Meeting Clinical Data Theralase Bladder Cancer Light-activated Therapy Urological Innovations
PRESS RELEASE published on 01/27/2025 at 22:15, 1 year ago Theralase(R) Interim Clinical Data to be Presented at the 2025 AUA Annual Meeting Theralase announces interim clinical data presentation at AUA Annual Meeting, showcasing promising results of light-activated Ruvidar™ in treating BCG-Unresponsive NMIBC CIS Theralase Bladder Cancer Interim Clinical Data Light-activated Ruvidar AUA Annual Meeting
BRIEF published on 12/09/2024 at 14:10, 1 year 2 months ago Theralase Expands Clinical Study Sites for Bladder Cancer Treatment in the U.S. Cancer Research Bladder Cancer Treatment Theralase Expansion Clinical Study Sites Ruvidar Activation
BRIEF published on 12/09/2024 at 14:10, 1 year 2 months ago Theralase élargit ses sites d'études cliniques pour le traitement du cancer de la vessie aux États-Unis Recherche Sur Le Cancer Expansion De La Théralase Traitement Du Cancer De La Vessie Sites D'études Cliniques Activation De Ruvidar
PRESS RELEASE published on 12/09/2024 at 14:05, 1 year 2 months ago Theralase(R) Launches Three New Clinical Study Sites in USA Theralase® launches new US Clinical Study Sites for bladder cancer treatment. Principal Investigators announced. Positive clinical data presented Clinical Data Theralase® Bladder Cancer US Clinical Study Sites
BRIEF published on 12/05/2024 at 13:05, 1 year 2 months ago Theralase Technologies Expands Bladder Cancer Study in Canada Canada Expansion Clinical Study Bladder Cancer Ruvidar Theralase Technologies
BRIEF published on 12/05/2024 at 13:05, 1 year 2 months ago Theralase Technologies étend son étude sur le cancer de la vessie au Canada Étude Clinique Cancer De La Vessie Ruvidar Technologies Théralase Expansion Au Canada
PRESS RELEASE published on 12/05/2024 at 13:00, 1 year 2 months ago Theralase(R) Launches New Clinical Study Site in Canada St. Joseph's Healthcare Hamilton joins Theralase®'s clinical investigation for bladder cancer treatment. Theralase® develops light-activated Ruvidar™ drug for BCG-Unresponsive NMIBC CIS patients Theralase® Bladder Cancer BCG-Unresponsive NMIBC CIS RuvidarTM Clinical Study Site
BRIEF published on 11/27/2024 at 23:10, 1 year 2 months ago Theralase publie son aperçu financier du troisième trimestre 2024 Placements Privés Dépenses De Recherche Et Développement Aperçu Financier De Theralase Chiffre D'affaires Et Marges Résultats De L'étude II
BRIEF published on 11/27/2024 at 23:10, 1 year 2 months ago Theralase Releases 3Q2024 Financial Overview Private Placements R&D Expenses Theralase Financial Overview Revenue And Margins Study II Results
Published on 02/11/2026 at 14:35, 2 hours 52 minutes ago Worksport Delivers Breakout Q4: Revenue Up 65% YoY, Gross Profit Up 380%
Published on 02/11/2026 at 14:30, 2 hours 57 minutes ago Sekur Private Data CEO Updates on Growth, Market Expansion, Corporate Developments and New Product Launch
Published on 02/11/2026 at 14:00, 3 hours 27 minutes ago Organto Foods Inc. Expands Scalable and Flexible Logistics Platform to Support 2026 Growth
Published on 02/11/2026 at 14:00, 3 hours 27 minutes ago PPX Mining Provides Operational and Corporate Update
Published on 02/11/2026 at 14:00, 3 hours 27 minutes ago Meta Critical Minerals Engages Quad Consulting Group to Advance Table Mountain Silica Project Development Strategy
Published on 02/11/2026 at 17:00, 27 minutes ago Mutares has completed the acquisition of Venator Ultramarine Blue Pigments business from Venator France SAS
Published on 02/11/2026 at 16:40, 47 minutes ago Guidepoint Launches Guidepoint360 Mobile App, Delivering AI-Driven Research Whenever It's Needed
Published on 02/11/2026 at 16:00, 1 hour 27 minutes ago Eleving Group: the recording of 12M 2025 earnings call
Published on 02/11/2026 at 15:04, 2 hours 23 minutes ago Form 8.3 - The Vanguard Group, Inc.: JTC plc
Published on 02/11/2026 at 15:03, 2 hours 24 minutes ago Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc
Published on 02/11/2026 at 11:25, 6 hours 2 minutes ago Innelec : Mise à disposition du rapport financier semestriel 2025-26
Published on 02/11/2026 at 08:00, 9 hours 27 minutes ago Imerys-press-release French State acquisition stake Emili Lithium
Published on 02/11/2026 at 08:00, 9 hours 27 minutes ago Imerys-communique-de-presse prise participation Etat Français Projet lithium Emili
Published on 02/10/2026 at 18:24, 23 hours 3 minutes ago Mersen: Number of shares and voting rights as of January 31, 2026
Published on 02/10/2026 at 18:24, 23 hours 3 minutes ago Mersen : nombre d'actions et de droits de vote au 31 janvier 2026
